[go: up one dir, main page]

HUP0002521A2 - A paclitaxel ónium sói, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények - Google Patents

A paclitaxel ónium sói, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0002521A2
HUP0002521A2 HU0002521A HUP0002521A HUP0002521A2 HU P0002521 A2 HUP0002521 A2 HU P0002521A2 HU 0002521 A HU0002521 A HU 0002521A HU P0002521 A HUP0002521 A HU P0002521A HU P0002521 A2 HUP0002521 A2 HU P0002521A2
Authority
HU
Hungary
Prior art keywords
paclitaxel
onium salts
medicaments
producing
same
Prior art date
Application number
HU0002521A
Other languages
English (en)
Inventor
George Digenis
Kenneth H. Kortright
Original Assignee
Baker Norton Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharmaceuticals, Inc. filed Critical Baker Norton Pharmaceuticals, Inc.
Publication of HUP0002521A2 publication Critical patent/HUP0002521A2/hu
Publication of HUP0002521A3 publication Critical patent/HUP0002521A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A paclitaxel új 2'-ónium-sói emlősökön prodrugként hatnak miközben invivo paclitaxel keletkezik. A találmány ilyen óniumsókra éselőállítási eljárásukra vonatkozik; továbbá az új sókat tartalmazógyógyászati készítményekre, melyek alkalmasak paclitaxel terápiáraszoruló betegeknek való beadásra. Ó
HU0002521A 1997-06-20 1997-06-20 Onium salts of paclitaxel, process for producing them and medicaments comprising the same HUP0002521A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/010746 WO1998058927A1 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Publications (2)

Publication Number Publication Date
HUP0002521A2 true HUP0002521A2 (hu) 2001-06-28
HUP0002521A3 HUP0002521A3 (en) 2002-04-29

Family

ID=22261122

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002521A HUP0002521A3 (en) 1997-06-20 1997-06-20 Onium salts of paclitaxel, process for producing them and medicaments comprising the same

Country Status (10)

Country Link
EP (1) EP1001769B1 (hu)
JP (1) JP2002505682A (hu)
AT (1) ATE219363T1 (hu)
AU (1) AU3574097A (hu)
CA (1) CA2294606A1 (hu)
DE (1) DE69713526D1 (hu)
HU (1) HUP0002521A3 (hu)
IL (1) IL133585A0 (hu)
SK (1) SK182599A3 (hu)
WO (1) WO1998058927A1 (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002064132A2 (en) * 2001-01-18 2002-08-22 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
WO2006089209A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
CA2692417C (en) 2007-07-03 2017-03-21 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
EP2859916B1 (en) 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
CN109608436B (zh) * 2011-04-08 2022-10-11 斯法尔制药私人有限公司 取代的甲基甲酰基试剂及使用所述试剂改进化合物物理化学和/或药代动力学性质的方法
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
CA2890190A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
SI3300745T1 (sl) 2013-02-15 2020-01-31 The Regents Of The University Of California Himerni antigenski receptor in postopki njihove uporabe
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
AU2014354643B2 (en) 2013-11-27 2020-03-05 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
ES2833157T3 (es) 2014-02-19 2021-06-14 Aviv Therapeutics Inc Amidas políciclicas de unión a aldehído deshidrogenasa 2 mitocondrial (aldh2) y su uso para el tratamiento del cáncer
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
WO2017087723A1 (en) 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3463308B1 (en) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
US12187801B2 (en) 2017-01-18 2025-01-07 Exuma Biotech Corp. Chimeric antigen receptors against AXL or ROR2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN111065623B9 (zh) 2017-05-24 2024-10-25 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
WO2019152661A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
AU2019252676A1 (en) 2018-04-11 2020-11-26 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
MX2021012003A (es) 2019-04-02 2021-11-04 Kenjockety Biotechnology Inc Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
EP4097134A1 (en) 2020-01-29 2022-12-07 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
US20230212305A1 (en) 2020-06-04 2023-07-06 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
US20230192902A1 (en) 2020-06-04 2023-06-22 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN116490522A (zh) 2020-09-02 2023-07-25 肯乔克蒂生物技术股份有限公司 抗abcc1抗体及其应用
WO2022103603A1 (en) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
CA3201005A1 (en) 2020-11-20 2022-05-27 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4013595A (en) * 1995-10-27 1997-05-15 Scripps Research Institute, The Method for treating cancer using taxoid onium salt prodrugs
CN1261275A (zh) * 1997-05-27 2000-07-26 巴克·诺顿药物有限公司 给予病人口服紫杉烷类药物的方法和组合物

Also Published As

Publication number Publication date
EP1001769B1 (en) 2002-06-19
HUP0002521A3 (en) 2002-04-29
IL133585A0 (en) 2001-04-30
AU3574097A (en) 1999-01-04
ATE219363T1 (de) 2002-07-15
WO1998058927A1 (en) 1998-12-30
EP1001769A1 (en) 2000-05-24
CA2294606A1 (en) 1998-12-30
SK182599A3 (en) 2000-07-11
EP1001769A4 (en) 2000-05-24
DE69713526D1 (de) 2002-07-25
JP2002505682A (ja) 2002-02-19

Similar Documents

Publication Publication Date Title
HUP0002521A2 (hu) A paclitaxel ónium sói, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
KR950703968A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 카르바마제핀 및 옥스카르바제핀의 적용(application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries)
ES2167608T3 (es) Composicion basada en monoxido de nitrogeno como medicamento.
AR020662A1 (es) Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento.
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
DE69627690D1 (de) Liposomale formulierungen von mitoxantron
IL112664A (en) 4-amino derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
IL112667A (en) 6-substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
ATE219670T1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
ATE173626T1 (de) Verwendung eines ascorbyl-tocopherylphosphats zur herstellung eines arzneimittels zur behandlung der pankreatitis
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
AU5372199A (en) Cyclopentabenzofuran derivatives and their use
DE69005860D1 (de) Verwendung von 5'-Deoxy-5'-methylthioadenosin S-adenosylmethionin und dessen Salzen zur Herstellung von Seborrhea vermindernden Arzneimitteln.
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
MX9800622A (es) Agentes terapeuticos mejorados.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.